

# PRESS RELEASE



June 13, 2017, Lund, Sweden

## **Immunovia's biomarker signature for the diagnosis of pancreatic cancer now patented in Japan**

LUND, Sweden — Immunovia is delighted to announce the grant by the Japanese Patent Office of a patent for its biomarker signature for the diagnosis of pancreatic cancer. Japanese Patent No. JP 6115801, is the first patent awarded to Immunovia in Japan covering its proprietary IMMray™ PanCan-d test.

Immunovia CEO, Mats Grahn, commented "The grant of this Japanese patent is a significant achievement for Immunovia as it provides robust patent protection for our IMMray™ PanCan-d test in an important commercial market. Immunovia is fully committed to bringing to market this proprietary test enabling the early diagnosis of pancreatic cancer. Effective patent protection is vital in order to safeguard Immunovia's R&D investment in such novel diagnostic tests and our new Japanese patent is a valuable addition to our IP portfolio".

### **For more information, please contact:**

#### **Mats Grahn**

Chief Executive Officer, CEO, Immunovia

Tel.: +46-70-5320230

Email: mats.grahn@immunovia.com

### **About Immunovia**

Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia's strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia's core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: [www.immunovia.com](http://www.immunovia.com))

This information is information that Immunovia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above.

Immunovia's shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildecos is the company's Certified Adviser. For more information, please visit [www.immunovia.com](http://www.immunovia.com).

###